Premium
Emblica officinalis (Amla) improves glucose regulation by modulating hepatic nuclear transcription factor, peroxisome proliferator‐activated receptor (PPAR)
Author(s) -
Buesa Lance Martinez,
Nerurkar Pratibha Vivek
Publication year - 2010
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.24.1_supplement.661.2
Subject(s) - peroxisome proliferator activated receptor , medicine , endocrinology , nuclear receptor , peroxisome proliferator activated receptor alpha , transcription factor , emblica officinalis , officinalis , receptor , chemistry , protein kinase b , pharmacology , signal transduction , biochemistry , traditional medicine , gene
Ayurvedic medicine Emblica officinalis (amla, EO) has been traditionally used as rejuvenative and anti‐inflammatory therapy. The objective of our study was to investigate the anti‐diabetic effects of EO in mice fed 58% kcal high‐fat‐diet (HFD) for 16 weeks. Male C57BL/6J mice were randomized into four groups: 1) control, 2) EO (10% w/w), 3) HFD and 4) HFD + EO. After 16 weeks, EO had no significant effect on daily food intake but improved liver weights, plasma and hepatic glutathione, fasting glucose as well as glucose and insulin tolerance in mice fed HFD. Mechanistic studies indicated that EO normalized hepatic mRNA expression of nuclear transcription factor, peroxisome proliferator‐associated receptor alpha (PPARα) and improved hepatic insulin signaling as measured by phosphorylation of Akt proteins by Western blot. Future studies are warranted to identify the active components and physiologically effective doses of EO. [Grants: NCCAM (R21AT003719), USDA‐CREES (2004‐34135‐15182)].